The Chinese University of Hong Kong
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1963-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.cuhk.edu.hk
Clinical Trials
1.3k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (946 trials with phase data)• Click on a phase to view related trials
Effectiveness of Low-Level Light Therapy for Vocal Fatigue
- Conditions
- Vocal Fatigue
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 22
- Registration Number
- NCT07062302
- Locations
- 🇭🇰
The Chinese University of Hong Kong, Shatin, N.t., Hong Kong
Impact of Chronotype-Based Time-Restricted Eating on Visceral Fat and Metabolic Health in Physically Inactive Adults With Central Obesity
- Conditions
- Central ObesityTime Restricted Eating
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 90
- Registration Number
- NCT07062315
- Locations
- 🇨🇳
Department of Sports Science and Physical Education, The Chinese University of Hong Kong, Hong Kong, China
The Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 110
- Registration Number
- NCT07057375
- Locations
- 🇭🇰
Prince of Wales Hospital, Sha Tin, Hong Kong
The Effects of a Nurse-led Community-based Sailing Programme on Resilience of School-aged Children With Autism: An RCT
- Conditions
- Autism Spectrum DisorderResilience
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 184
- Registration Number
- NCT07056387
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy; a Placebo-controlled Trial
- Conditions
- Myocardial Infarction (MI)Cardiovascular EventsPost Polypectomy Bleeding in Antiplatelet Patients
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2025-07-07
- Last Posted Date
- 2025-07-07
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 2514
- Registration Number
- NCT07052799
- Prev
- 1
- 2
- 3
- 4
- 5
- 261
- Next
News
Immuno Cure Partners with PharmaJet to Advance HIV Therapeutic DNA Vaccine Using Needle-Free Delivery Technology
Immuno Cure and PharmaJet signed a collaboration agreement to evaluate the HIV therapeutic DNA vaccine ICVAX using PharmaJet's needle-free Tropis intradermal delivery system in clinical trials.
Cornerstone Robotics Secures $70M Series C to Challenge da Vinci's Surgical Robot Dominance
Cornerstone Robotics raised over $70 million in Series C funding led by EQT to accelerate commercialization of its Sentire endoscopic surgical system and challenge established players like da Vinci.
New Mainland Chinese Cancer Drug Shows Promising Results in Phase 1 Trial
A multinational study led by Chinese University of Hong Kong researchers found that D3S-001, a mainland-developed cancer drug, effectively treats tumors driven by KRAS-G12C gene mutations.
AI-Assisted Colonoscopy Boosts Adenoma Detection Rate by 40% in Junior Endoscopists
CU Medicine research demonstrates that AI-assisted colonoscopy significantly improves adenoma detection rates by 40% among junior endoscopists with less than three years of experience.
Microbiome Modulation with SIM01 Shows Promise for Long COVID Treatment in Randomized Trial
A randomized, triple-blind, placebo-controlled clinical trial by Chinese University of Hong Kong demonstrated that SIM01, an oral microencapsulated live bacteria formula, significantly improved long COVID symptoms compared to placebo.
D3Bio's Novel KRAS-G12C Inhibitor Shows Promising Results in Phase 1 Cancer Trial
A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.